Our study further evaluated the clinical relevanceof OCIAD2 in lung adenocarcinoma patients within the TwCM cohort,which features comprehensive proteogenomic profiles and clinical data.This approach helped minimize the potential bias arising from incompleteclinicopathological information that may not be fully clarified inpublic databases. This evidence concerns the gene OCIAD2 and lung adenocarcinoma.